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Background: The aim of this study was to investigate the use of imaging techniques to predict the
response to cardiac resynchronization therapy (CRT) in patients with non-ischemic cardiomyopathy
(NICM) by simultaneous assessment of left ventricular (LV) dyssynchrony and myocardial perfusion in
a single nuclear scan of the heart.
Methods: Patients indicated for CRT device implantation underwent a resting myocardial perfusion
assessment with single photon emission computed tomography (MP-SPECT) examination using
technetium-99 m methoxyisobutylisonitrile prior to device implantation. CardioGRAF and cardioBull
software (FUJIFILM RI Pharma, Tokyo, Japan) were used to analyze the LV mechanical dyssynchrony and
myocardial viability, respectively. Patient follow-ups were performed at 6 months after device
implantation. CRT response was deﬁned as a Z10% decrease in the LV end systolic volume.
Results: A total of 43 patients with NICM were analyzed. Using the cutoff points of 6.2 for the
dyssynchrony index and 66% for LV myocardial perfusion, the combined indices predicted CRT response
with a sensitivity of 77.8% and speciﬁcity of 91.2%.
Conclusion: Combined assessment of MP-SPECT and a measure of LV mechanical dyssynchrony showed
good predictive ability in patients with non-ischemic heart failure.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Cardiac resynchronization therapy (CRT) has been demon-
strated to improve symptoms, quality of life, functional status,
and reduce mortality and heart failure-related hospitalizations in
patients with New York Heart Association (NYHA) class III or IV
heart failure and electrocardiographic evidence of ventricularrt Rhythm Society. Published by E
: þ81 3 3673 1229.dyssynchrony (QRS duration Z120 ms) [1–3]. However, approxi-
mately one-third of patients receiving CRT fail to respond to
treatment [4]. Analyses that accounted for the placebo effect and
the use of remodeling rather than functional endpoints found an
even higher non-response rate [5]. Given the number of device
and/or procedure-related adverse events as well as the economic
burden of CRT, numerous efforts have been made to identify
parameters that could be used to improve patient selection and
reduce the incidence of non-response.
Recently, it has been shown that the presence of posterolateral
scar burden can predict CRT non-response [10,11]. Birnie et al.lsevier B.V. All rights reserved.
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mining CRT response in non-ischemic cardiomyopathy patients [10].
Bleeker et al. found that the patients most likely to improve after
CRT were those without transmural scar tissue in the poster-
olateral wall and severe left ventricular mechanical dyssynchrony
(LVMD) at baseline [11]. These ﬁndings were attributed to
ineffective pacing due to nonviable scar tissue in the region of
the LV pacing lead. This observation supports combined assess-
ment of both LVMD and scar burden prior to CRT implantation to
verify the characteristics of the area targeted for LV pacing. Given
these ﬁndings, there has been increased interest in the use of
nuclear imaging for predicting CRT response [12,13]. Myocardial
perfusion assessment with single photon computed tomography
(MP-SPECT) provides information regarding LV myocardial viabi-
lity and could enable evaluation of LV scar burden. A software tool
that enables the simultaneous estimation of regional LV function
and wall motion synchrony in combination with MP-SPECT has
been validated [14–16]. Since the phase analysis tool is largely
automatic, it is less prone to inter observer errors than echocar-
diography. Additionally, it does not require the considerable
specialized expertise required to perform these assessments by
echocardiography.2. Methods
2.1. Patients and study procedures
A total of 53 patients who had heart failure, were scheduled
for implantation of their ﬁrst CRT device, and had agreed to
undergo nuclear imaging at 10 centers were prospectively stu-
died. The Medical Ethics Committee at each participating center
approved the study protocol, and all patients provided written
informed consent. Patients were selected for CRT implantation
based on the Japanese Circulation Society Guideline [17,18]. The
basic criteria were as follows: NYHA class III or IV, QRS duration
Z130 ms, LV ejection fraction (LVEF) r35%, and non-ischemic
heart failure as documented by exclusion of coronary artery
disease by using angiography. Based on the QRS duration, LVEF,
and prior history of heart failure hospitalizations, NYHA class I
and II patients could be included at the physician’s discretion.Fig. 1. Change in the regional LV chamber volume. Global and regional time–volume cu
3 harmonics; the ﬁrst derivative curve was simultaneously created from the time–volum
curves and the ﬁrst derivative curves.Patients who had a life expectancy o6 months; were scheduled
for heart surgery, including percutaneous coronary intervention;
and/or who could not be followed for 6 months were excluded
from the study.
The study was conducted as follows: prior to CRT implanta-
tion, all patients underwent a resting MP-SPECT examination
using technetium-99 m methoxyisobutylisonitrile (TcMIBI). Scan-
ning procedures were performed according to the guidelines of
the Japanese Society of Nuclear Medicine Technology working
group [19], which are comparable with the American Society of
Nuclear Cardiology [20] and European Association of Nuclear
Medicine/European Society of Cardiology [21] guidelines. Free
computer software, that is, cardioGRAF and cardioBull (FUJIFILM
RI Pharma, Tokyo, Japan), were used to assess LVMD and LV
myocardial perfusion, respectively. These programs have been
validated and assessed in previous studies [16,36] with respect to
the performance level of quantitative assessment for LV dyssyn-
chrony. These software programs have been described in further
detail in the sections on assessment measures. The MP-SPECT
examination was repeated 6 months after CRT implantation, and
the patients’ clinical status and nuclear cardiographic ﬁndings
were reassessed. All analyses of data derived from using the
cardioGRAF and cardioBull were performed at a core lab in
Edogawa Hospital, Tokyo, Japan.2.2. Assessment of left ventricular mechanical dyssynchrony
Regional contraction timing in the LV was computed and
visualized with cardioGRAF software, which processes imaging
data acquired by gated MP-SPECT, as described previously by
Takahashi et al. [22]. Brieﬂy, the LV was divided into 17 volume
segments [23] and the regional wall motion and change in
myocardial wall thickening of each segment were estimated
[24–26]. The time-based variation in volume was measured for
each segment. The onset of a cardiac rhythm was triggered at the
peak of the R-wave, and end systole was determined based on the
detection of the bottom of the third-derivative of the time–
volume curve (i.e., the contraction velocity) (Fig. 1). End systole
of the whole LV was estimated as the instant at which the sum of
all of the segments was minimal (Fig. 2) [16]. The cardioGRAF
software has been validated by Yamamoto et al. [16] andrves were generated from the data obtained by Fourier curve-ﬁtting analysis with
e curve. The global and regional parameters were obtained from the time–volume
Fig. 2. Main window of the cardioGRAF Software. CardioGRAF plots regional left ventricular (LV) time–volume curves. The dashed lines indicate the ‘‘time to peak
ejections’’ (A), ‘‘time to end systoles’’ (TES; B), and ‘‘time to peak ﬁllings’’ (C) for each of the LV segments.
Fig. 3. Deﬁnition of the dyssynchrony index. (a) SDI:LVMD-SL was deﬁned as the value obtained on subtracting the mean of the time to end systole (TES) of the left
ventricular (LV) septum (4 segments) from the mean of the TES of the LV lateral wall (4 segments), dividing the resultant value by the R–R interval (ms), and multiplying
the ﬁnal value by 100. (b) SDI:LVMD-GL was deﬁned as the value obtained on determining the standard deviation of TES in 12 segments excluding the apical segments,
dividing this standard deviation value by the R–R interval (ms), and multiplying the ﬁnal value by 100.
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by Nakajima et al. [27].
2.3. Development and evaluation of the systolic dyssynchrony index
We developed 2 types of systolic dyssynchrony indices (SDIs)
in order to assess the quantitative measure of LVMD. One was
used to quantify the LVMD between the LV septum and LV lateral
wall (SDI:LVMD-SL), and the other was used to quantify the global
LVMD (SDI:LVMD-GL). SDI:LVMD-SL was deﬁned as the value
obtained on subtracting the mean of the time to end systole (TES;
Fig. 1) of the LV septum (4 segments) from the mean of the TES
of the LV lateral wall (4 segments), dividing the resultant value
by the R–R interval (ms), and multiplying the ﬁnal value by 100
(Fig. 3a).SDI: LVMD-GL was deﬁned as the value obtained on determin-
ing the standard deviation of TES in 12 segments excluding the
apical segments, dividing this standard deviation value by the
R–R interval (ms), and multiplying the ﬁnal value by 100 (Fig. 3b).
It was assumed that measurements in the apex area did not
contribute to the SDI:LVMD-GL.
2.4. Assessment of regional left ventricular myocardial perfusion
LV myocardial perfusion was assessed by the uptake rate in
each of the 17 segments of the LV, as calculated by the software
and displayed in the form of a bull’s eye map. Toyota et al. [28]
reported that bull’s eye mapping with this software tool provided
a simple and useful numerical parameter for diagnosing myocar-
dial viability with high speciﬁcity and high sensitivity.
Table 1
Baseline patient characteristics and medications used.
CRT responder
(N¼34, 79%)
CRT non-responder
(N¼9, 21%)
P-
value*
Age (years) 68.1710.8 69.478.6 0.93
Gender (M/F) 24/10 8/1 0.26
NYHA Class (I, II, III,
IV)
2/8/17/7 0/0/9/0 0.65
QRS duration (ms) 155.673 5.2 156.9727.6 0.92
LBBB/RBBB/IVCD/
narrow
20/5/4/5 4/2/3/0 0.28
Rhythm (SR/AF/paced/
other)
23/5/4/2 5/2/2/0 0.68
LVEF (%) 23.978.9 26.6711.7 0.47
LVEDV (mL) 298.07121.3 278.17136.5 0.67
LVESV (mL) 231.37105.4 209.17119.6 0.60
BNP (pg/mL) 680 (292–1085) 401 (246–778) 0.24
6-minute hall walk
distance (m)
325 (240–415) 340 (280–400) 0.95
% V pacing 96.978.4 96.973.5 0.98
Inotropic agents (iv) 5 (14.7%) 0 (0%) 0.22
Beta-blocker 25 (73.5%) 9 (100%) 0.08
ACE inhibitor 13 (38.2%) 4 (44%) 0.74
ARB 11 (32.4%) 2 (22.2%) 0.56
Spironolactone 16 (47.1%) 5 (55.6%) 0.65
Loop diuretic 27 (79.4%) 9 (100%) 0.14
Digitalis 1 (2.9%) 3 (33.3%) 0.005
Statin 6 (17.6%) 1 (11.1%) 0.61
NYHA¼New York Heart Association, LBBB¼ left branch bundle block, RBBB¼right
branch bundle block, IVCD¼ interventricular conduction delay, SR¼sinus rhythm,
AF¼atrial ﬁbrillation, LVEF¼ left ventricular ejection fraction, LVEDV¼ left ven-
tricular end diastolic volume, LVESV¼ left ventricular end systolic volume,
BNP¼brain natriuretic protein, ACE¼angiotensin-converting enzyme,
ARB¼angiotensin receptor blocker.
n Results have been expressed as mean7standard deviation values. The
Student-t test was applied for absolute values and the chi-square test was applied
for proportional values. The p-value represents the comparison between the
responder and non-responder groups.
Table 2
Uptake rate of Tc-MIBI (%) in all patients, responders, and non-responders.
Total
(N¼43)
Responders
(N¼34)
Non-
responders
(N¼9)
p-
value*
Uptake at the mid-
inferolateral wall
71711 74710 61710 o0.001
n The p-value represents the comparison between the responder and non-
responder groups.
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Patients received commercially available CRT devices with and
without a deﬁbrillator (N¼39 and 4, respectively) with implanta-
tion of a standard active-ﬁxation pacing lead in the right atrium
and a high-voltage lead in or near the right ventricular apex.
A transvenous LV lead was positioned in a lateral or posterolateral
branch of the coronary vein. The atrioventricular and interven-
tricular delays were optimized using Doppler echocardiography
by the method chosen at the physicians’ discretion.
2.6. Deﬁnition of a CRT responder
CRT response was deﬁned as a Z10% decrease in the LV end-
systolic volume (LVESV) at 6 months after CRT implantation, as
measured by the cardioGRAF software. The deﬁnition of CRT
response was based on the results of a study conducted by Yu
et al., who found that LV reverse remodeling was the best
predictor of long-term survival after CRT [29]. A Z10% improve-
ment in LVESV was predictive of long-term survival and is an
objective measure of CRT response.
2.7. Statistical analysis
Using the indicators obtained by cardioGRAF and cardioBull as
independent variables, the odds ratio (OR) and the 95% conﬁdence
interval (CI) were calculated with the multivariable logistic
regression model. After correction for the confounding explana-
tory variables, the degree of CRT response prediction of each
independent cardioGRAF and cardioBull indicator was evaluated.
The hazard ratio (HR) was calculated using the multivariateCox proportional hazards model. When the predictive factors
obtained from the aforementioned model were in the form of
continuous data, the cutoff points for LVMD and LV scar burden
were examined using the receiver-operating characteristic (ROC)
curves.3. Results
3.1. Study population
Of the 53 patients enrolled in the study, 3 patients died and
7 were lost to follow-up prior to 6 months; 43 patients completed
the 6-month follow-up. Thus, a total of 43 heart failure patients
with no angiographic evidence of coronary artery disease were
included in the analysis. According to the predeﬁned deﬁnition of
CRT response as a Z10% decrease in LVESV at 6 months, there
were 34 responders and 9 non-responders. The baseline char-
acteristics of the study population and baseline medications are
shown in Table 1. There were no baseline differences between the
CRT responders and non-responders, with the exception of
digitalis use in non-responders (Table 2).
3.2. Predicting CRT response
3.2.1. LVMD index (cardioGRAF)
Using cardioGRAF, we found that SDI:LVMD-SL is a better
predictor of systolic dyssynchrony than SDI:LVMD-GL (crude OR:
1.12, 95% CI: 1.021.23, p¼0.018) (Fig. 4a). ROC analysis showed
that the area under the curve (AUC) was 0.737. Using a DI cutoff
point of 6.2 resulted in 77.8% sensitivity and 64.7% speciﬁcity for
the prediction of CRT response (Fig. 4b).
3.2.2. Regional LV myocardial perfusion score (cardioBull)
Using the % uptake values in the 17 segments as independent
variables, the ORs and 95% CIs were calculated with the multi-
variate logistic regression model. The decrease in the % uptake in
the basal inferolateral, middle inferolateral, and middle antero-
lateral segments was a signiﬁcant (po0.05) predictor of CRT
response (Fig. 5a). Among these 3 regions, the middle inferolateral
region is usually most adjacent to or corresponds with the
position of the LV lead placement, and showed the highest OR
of 0.89 (95% CI: 0.81–0.97), thus it was a segment of particular
interest. ROC analysis of this segment showed that the AUC was
0.858. Using a % uptake cutoff point of 66% provided a 77.8%
sensitivity and 76.5% speciﬁcity for the prediction of CRT response
(Fig. 5b).
3.2.3. Combined index of LVMD and myocardial perfusion in the
middle inferolateral area
The combined indexes of LVMD and myocardial perfusion in
the middle inferolateral area for the prediction of CRT response
are shown in Fig. 6. When the elements of LVMD and regional
myocardial perfusion were combined, the combined AUC was 0.895.
Moreover, when the SDI:LVMD-SL calculated by cardioGRAF was
Fig. 4. (a) The dyssynchrony index calculated by the cardioGRAF software for the prediction of response to cardiac resynchronization therapy. (b) Receiver-operating
characteristic analysis of left ventricular (LV) mechanical dyssynchrony for the prediction of cardiac resynchronization therapy response.
Fig. 5. (a) Regional left ventricular (LV) myocardial perfusion calculated by the cardioBull software for the prediction of response to cardiac resynchronization therapy.
(b) Receiver-operating characteristic analysis of regional LV myocardial perfusion for the prediction of cardiac resynchronization therapy response.
Fig. 6. Receiver-operating characteristic analysis of the combined index of left
ventricular (LV) mechanical dyssynchrony and myocardial perfusion in the middle
inferolateral area for the prediction of cardiac resynchronization therapy response.
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by cardioBull was Z66%, CRT response was predicted with sensi-
tivity of 77.8% and speciﬁcity of 91.2% (Fig. 6).4. Discussion
The main ﬁndings of this study are as follows. First, the LVMD
index calculated by the nuclear imaging analysis with cardioGRAF
phase analysis software had a moderate predictive value for
6-month CRT response (deﬁned as 410% reduction in LVESV).
Second, regional myocardial perfusion assessment with nuclear
imaging analysis using cardioBull software yielded a greater
predictive capability for CRT response. In particular, the extent
of low perfusion in the middle inferolateral wall indicated by
cardioBull was highly relevant to the response. Third, the com-
bined assessment of myocardial perfusion in the middle infer-
olateral wall and LVMD with nuclear imaging analysis using
cardioGRAF and cardioBull, respectively, augmented the predic-
tive capability for CRT response.
As with other phase analysis tools, computing quantiﬁed
cardiac function parameters with cardioGRAF is largely auto-
matic. Therefore, the considerable level of expertise required
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required. In an evaluation of the cardioGRAF tool, Takahashi
et al. [22] demonstrated that the inter- and intra-observer
reproducibility (i.e., coefﬁcient of variation error) for the time to
contraction (i.e., time from the onset of the R-wave to end systole)
was 4.8% and 3.2%, respectively.
Patients with ischemic cardiomyopathy were not included in
this study because of the potential difﬁculties in accurate depic-
tion of the LV endocardium with gated MP-SPECT due to severe
perfusion defects. The results of the present study, however,
suggested that there could be severe perfusion defects even in
the hearts of patients with non-ischemic cardiomyopathy. The
growing numbers of patients eligible for CRT due to an aging
population and expanded indications, including mild heart failure
[30,31], in combination with evidence that the actual non-
responder rate may be even higher than initial estimates [32],
underscores the ongoing need for methods to predict the CRT
response. Reducing the non-response rate requires identiﬁcation
of appropriate parameters, cutoff values, and assessment techni-
ques. Starting with the early stages of CRT, the use of a wide QRS
duration as a patient selection criterion has been questioned;
rather, the presence of LVMD was proposed as an important
predictor of a ﬁrm response to CRT [6]. Direct estimation of LVMD
using an imaging modality has been proposed as a method to
improve patient selection for CRT and reduce the incidence of
non-responses. Multiple small single center studies have demon-
strated the application of a variety of echocardiographic measures
of LVMD to predict CRT response with a high degree of sensitivity
and speciﬁcity [6–8]. However, these results have not been
duplicated in a large-scale multicenter study. The Predictors of
Response to CRT (PROSPECT) trial, a prospective, multicenter
study evaluating 12 echocardiographic parameters of LVMD,
found only modest sensitivity and speciﬁcity in predicting CRT
response [9]. Although each of the 53 participating centers was
required to obtain accreditation from an echocardiography core
laboratory, Chung et al. found that differences in technology
platforms, training standards, and measurement analytics limited
the reproducibility of the imaging methods in a non-specialized
multicenter setting [9]. In Japan, Seo et al. concluded that
echocardiographic parameters did not show signiﬁcant power to
detect CRT responders independently [35].
Therefore, other imaging techniques and tools have been
evaluated. The results of this study add to the body of evidence
demonstrating the value of SPECT and the need for a multi-
factorial approach to patient selection for CRT and in evaluating
potential predictors of CRT response in non-ischemic patients.
Bleeker et al. [11] used magnetic resonance imaging (MRI) to
assess the extent of myocardial scar tissue. In addition to the
automaticity provided by software analysis tools, SPECT offers the
additional advantages of accessibility and usability in patients
with pacemakers and/or other non-MRI conditional implantable
medical devices.
With regard to the speciﬁc measures used in this study, a wide
QRS has been associated with ventricular dyssynchrony and used
as a patient selection criterion for CRT since its development.
However, since large-scale, prospective, randomized studies have
demonstrated that approximately one-third of patients with
electrographic evidence of ventricular dyssynchrony fail to
respond to CRT, attempts have been made to reﬁne patient
selection criteria. The results of this study suggest that not only
measurement of mechanical dyssynchrony but also assessment of
myocardial viability is an important factor in patient selection for
CRT. Therefore, the Find Index by Nuclear Imaging for Dyssyn-
chrony (FIND) study is unique in terms of evaluating a non-
ischemic population and using the cardioGRAF and cardioBull
software tools simultaneously.In studies on the effect of posterolateral scar tissue on CRT
response, Bleeker et al. [11] demonstrated that patients with
transmural scar tissue in the posterolateral wall do not respond to
CRT even in the presence of extensive mechanical dyssynchrony.
Birnie et al. [10] reported that the location of scar tissue (lateral
wall versus global or septal scar tissue) was a predictor of CRT
response. To assess the relevance of the results of the FIND study
in comparison to these studies, it is helpful to review the results
of Udelson et al. [33] who compared SPECT imaging with 201Tl
and MIBI for the determination of reversible and irreversible
myocardial dysfunction after revascularization. The study found
that both agents comparably predicted reversibility of contractile
dysfunction after revascularization and that an arbitrary cutoff
point of 60% of peak activity separated the regions of reversible
and irreversible myocardial function. The cutoff value of 66% in
this study was close to this value, demonstrating the potential
value of the methods used to determine scar burden.
A recent large-scale study conducted by Adelstein et al. that
used SPECT to evaluate the effect of scar burden from prior
myocardial infarction on outcomes following CRT is also notable
[34]. The study, which included patients with both non-ischemic
and ischemic heart failure etiologies found that a high scar
burden was associated with reduced survival and a lack of LV
functional improvement, whereas baseline dyssynchrony did not
predict CRT outcomes. The study suggests a possible utility of
both cardioGRAF and cardioBull in an ischemic population.
Further evaluation of the methods and software tools used in
this study should be performed in a larger-scale prospective study
involving a prescriptive protocol for conducting SPECT imaging in
a broader population of patients eligible for CRT device
implantation.
Our results demonstrated a relatively higher response rate as
compared to other studies. Several studies have been published
on response rates in CRT. For example, the Japan Cardiac Resyn-
chronization Therapy Registry Trial (J-CRT) trial [35] reported that
63% of patients in the CRT group responded to the therapy as
volume responders. Comparing this result to that of our study, we
demonstrated a higher response rate. One of the reasons for this is
likely patient population differences, particularly with regard to
etiology. Our patient population solely included non-ischemic
patients, and it is well known that ischemic patients do not
respond well to CRT compared to non-ischemic patients [29].
Furthermore, we deﬁned responders as patients demonstrating
Z10% reduction of LVESV after CRT. This deﬁnition might classify
a larger proportion of patients as responders compared to the
standard deﬁnition of volume responders (i.e., 415% reduction of
LVESV after CRT).5. Limitations
The limitations of this study are the small total sample size,
lack of enrollment of consecutive patients, and the inclusion of
patients who did not meet the inclusion criteria (i.e., QRS duration
and NYHA classiﬁcation). The included patients may, therefore,
represent selection bias. Another limitation is that, although data
analysis using SPECT software was performed at a core lab and
scanning procedure was performed as per the guidelines, the
scanning environment, including the gamma camera, pixel size,
and technetium dose, varied between sites. Therefore, imaging
quality varied between centers. In addition, the temporal resolu-
tion of cardioGRAF is not high (16 points/cardiac cycle). This may
explain why the dyssynchrony predictive accuracy alone was not
deﬁnitive (AUC¼0.737).
T. Keida et al. / Journal of Arrhythmia 29 (2013) 180–1861866. Conclusions
Low myocardial perfusion of the lateral wall is an important
factor in determining the response to CRT in patients with non-
ischemic cardiomyopathy, and the detection of low perfusion
with SPECT analysis is a powerful tool to predict CRT response.
The combined assessment of low myocardial perfusion and LVMD
using automated software for SPECT analysis may augment the
predictive capability of CRT response.Disclosures
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